Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation

European Journal of Cancer

Volumn 43, Issue 10, 2007, Pages 1556-1563

  Hermsen, B B J ^a   Verheijen, R H M ^a   Menko, F H ^a   Gille, J J P ^a   van Uffelen, K ^a   Blankenstein, M A ^a   Meijer, S ^a   van Diest, P J ^b   Kenemans, P ^a   von Mensdorff Pouilly, S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BRCA1 2 mutations; MUC1; Natural antibodies

Indexed keywords

CA 15-3 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MUCIN 1;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; EVALUATION; FEMALE; GENE MUTATION; GENETIC RISK; HEREDITY; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; NETHERLANDS; PRIORITY JOURNAL; PROGNOSIS; SERUM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTIBODIES; ANTIBODY FORMATION; BREAST NEOPLASMS; CA-15-3 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOGLOBULIN M; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS;

EID: 34250012847     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.04.007     Document Type: Article

References (34)

1. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 5182 (1994) 66-71
2. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 6559 (1995) 789-792
3. Ford D., Easton D.F., and Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57 6 (1995) 1457-1462
4. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 20 (1997) 1401-1408
5. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 5645 (2003) 643-646
6. Bourne T.H., Campbell S., Reynolds K.M., et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 306 6884 (1993) 1025-1029
7. Vasen H.F., Haites N.E., Evans D.G., et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 34 12 (1998) 1922-1926
8. Sauven P. Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer 40 5 (2004) 653-665
9. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 21 (2002) 1609-1615
10. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 2 (1999) 77-84
11. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 21 (2002) 1616-1622
12. Tobacman J.K., Greene M.H., Tucker M.A., Costa J., Kase R., and Fraumeni J.F. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2 8302 (1982) 795-797
13. Madalinska J.B., Hollenstein J., Bleiker E., et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23 28 (2005) 6890-6898
14. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 2 (2004) 137-148
15. Finn O.J., and Forni G. Prophylactic cancer vaccines. Curr Opin Immunol 14 2 (2002) 172-177
16. Lollini P.L., and Forni G. Antitumor vaccines: is it possible to prevent a tumor?. Cancer Immunol Immunother 51 8 (2002) 409-416
17. Taylor-Papadimitriou J., Burchell J.M., Plunkett T., et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7 2 (2002) 209-221
18. Mensdorff-Pouilly S., Verstraeten A.A., Kenemans P., et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18 3 (2000) 574-583
19. Hirasawa Y., Kohno N., Yokoyama A., Kondo K., Hiwada K., and Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161 (2000) 589-594
20. Hamanaka Y., Suehiro Y., Fukui M., Shikichi K., Imai K., and Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103 1 (2003) 97-100
21. Sevilla C., Moatti J.P., Julian-Reynier C., et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 10 10 (2002) 599-606
22. Hogervorst F.B.L., Nederlof P.M., Gille J.J.P., et al. Large genomic deletions and duplications in the BRCA1 gene identified by a Novel Quantitative Method. Cancer Res 63 7 (2003) 1449-1453
23. Bon G.G., Kenemans P., Verstraeten R., van Kamp G.J., and Hilgers J. Serum tumour marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 174 (1996) 107-114
24. Kenemans P., Bon G.G., Kessler A.C., Verstraeten A.A., and van Kamp G.J. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125. Clin Chem 38 (1992) 1466-1471
25. Mensdorff-Pouilly S., Gourevitch M.M., Kenemans P., et al. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol 19 3 (1998) 186-195
26. Hoogerbrugge N., Bult P., de Widt-Levert L.M., et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21 1 (2003) 41-45
27. Zielinski C.C., Budinsky A.C., Wagner T.M., et al. Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers. Breast Cancer Res Treat 81 2 (2003) 99-105
28. Wolfram R.M., Budinsky A.C., Brodowicz T., et al. Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer 88 2 (2000) 239-244
29. Hermsen B.B., van Diest P.J., Berkhof J., et al. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 119 6 (2006) 1412-1418
30. von Mensdorff-Pouilly S., Petrakou E., Kenemans P., et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 86 5 (2000) 702-712
31. Karsten U., Serttas N., Paulsen H., Danielczyk A., and Goletz S. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumour-specific epitope of the epithelial mucin (MUC1). Glycobiology 14 8 (2004) 681-692
32. von Mensdorff-Pouilly S., Kinarsky L., Engelman K., et al. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology 15 8 (2005) 735-746
33. George S.K., Schwientek T., Holm B., Reis C.A., Clausen H., and Kihlberg J. Chemoenzymatic synthesis of sialylated glycopeptides derived from mucins and T-cell stimulating peptides. J Am Chem Soc 123 45 (2001) 11117-11125
34. Tarp M.A., Sorensen A.L., Mandel U., et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17 2 (2007) 197-209